Anti-tumor Drug Delivery and Tumor Therapy Based on Metal-organic Frameworks / 肿瘤防治研究

Metal-organic frameworks (MOFs) are mixed porous materials which are composed of metal clusters or ions and organic pillars. Given their channel tunability, high porosity, large specific surface area, and good biocompatibility, MOFs can be combined with various biological macromolecules. In recent years, they have been widely studied in the field of biomedicine, especially in the loading of anti-tumor drugs, showing great application prospects. Multifunctional anti-tumor MOF combined with different therapeutic methods provides a new idea and method for tumor treatment. On the basis of the structure of MOF, this paper introduces the advantages of using MOF to load anti-tumor drugs and reviews the application of MOF in tumor therapy.

Expression of PLEK2 in malignant tumors and its influence on invasion and metastasis / 国际外科学杂志

PLEK2 (Pleckstrin-2) is a subtype of platelets and leukocytes Pleckstrin, located at 14q23.3-q24.1. Its encoded protein contains 353 amino acids. It plays a role in a variety of cells other than immune cells. The research is relatively limited, mainly involved in the reorganization of cytoskeleton proteins and the regulation of cell extension and migration. PLEK2 plays an important role in the occurrence, development and metastasis of a variety of tumors, and can participate in the regulation of a variety of signal pathways, thereby regulating tumor cell proliferation, invasion and metastasis. PLEK2 is up-regulated in a variety of tumors and has carcinogenic properties. This article reviews the regulatory role of PLEK2 in tumorigenesis, development and metastasis and its impact on tumor prognosis.

Research progress on the expression of CPNE in malignant tumor and its effect on invasion and metastasis / 国际外科学杂志

Malignant tumor has become one of the main reasons threatening human health. Invasion and metastasis are the important biological characteristics of malignant tumor and the main cause of death of malignant tumor patients. CPNE is highly expressed in malignant tumors, and its family may interact with proteins and MicroRNA to participate in MAPK, PI3K/AKT and other signal pathways to mediate tumor cell proliferation, invasion and metastasis. This article reviews the expression of CPNE in malignant tumors and its effect on invasion and metastasis.

Meta-analysis of the clinical effect and safety of bevacizumab combined with FOLFOX in patients with advanced colorectal cancer / 国际外科学杂志

Objective:To systematically evaluate the clinical effect and safety of bevacizumab combined with FOLFOX regimen in patients with advanced colorectal cancer.Methods:An electronic search of Pubmed, Embase, CNKI and other Chinese and English databases were retried from their inception to December 2018 to identify relevant literatures, by taking "Bevacizumab, FOLFOX, Advanced Colorectal Cancer, Randomized Controlled Trial" as the keywords for retrieval. Patients were divided into a combination group (bevacizumab combined with FOLFOX program) and a control group (using FOLFOX program alone) according to the treatment method, using Revman 5.3 software for meta-analysis.Results:A total of 11 articles, involving 3178 patients, were included with 1599 in the combination group and 1579 in the control group. The objective group response rate ( OR=3.15, 95% CI: 2.25 ~ 4.40, Z=6.71, P<0.000 01) and disease control rate ( OR=2.73, 95% CI: 1.91 ~ 3.90, Z=5.49, P<0.000 1) in combination group were higher than those in the control group. In terms of adverse reactions, the incidence of gastrointestinal reactions in the combination group was higher than that in the control group ( OR=1.29, 95% CI: 1.07~1.55, Z=2.64, P=0.008 ), There was no significant difference in the incidence of liver injury, leukopenia, hypertension, and neurotoxicity between the two groups. Conclusion:Bevacizumab combined with FOLFOX regimen is more effective than FOLFOX regimen for patients with advanced colorectal cancer, but it will increase the risk of gastrointestinal reactions.

Thirty-Day Readmission After Radical Gastrectomy for Gastric Cancer: A Meta-analysis.

BACKGROUND: Readmission is a commonly accepted parameter to evaluate surgical quality, but previous studies reported inconsistent results in radical gastrectomy. The purpose of our study is to clarify the prevalence, potential causes, and risk factors of 30-d readmission after radical gastrectomy for gastric cancer. METHODS: PubMed and Embase were systematically searched from inception to September 2018 for any possible inclusion. Prevalence, potential causes, and risk factors of 30-d readmission in included studies were extracted using a standardized EXCEL table. The overall 30-d readmission rate was pooled using a random-effects model. Odds ratios with 95% confidence intervals were used to estimate potential risk factors for 30-d readmission. Publication bias was assessed using a funnel plot and statistical tests. RESULTS: A total of nine studies with 16,581 patients were included in the current meta-analysis. The pooled 30-d readmission rate after radical gastrectomy was 8% (95% confidence interval, 0.04-0.12). Nutritional difficulty and surgical site infections were the main causes for 30-d readmission. Cardiovascular comorbidity, total gastrectomy, nutritional risk screening 2002 score ≥3, any complications, laparoscopic gastrectomy, and C-reactive protein on postoperative day 3 ≥12 were strong predictors for 30-d readmission, whereas combined multiorgan resection was a weaker predictor. No significant publication bias was identified through the funnel plot and statistical tests. CONCLUSIONS: The 30-d readmission rate after radical gastrectomy ranges from 4% to 12% and can mainly result from nutritional difficulty and surgical site infections. Nutritional risk screening 2002 score ≥3, cardiovascular comorbidity, total gastrectomy, any complications, and laparoscopic gastrectomy were potential risk factors for 30-d readmission.

Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis.

BACKGROUND: The prognostic value of Stathmin 1 (STMN1) in malignant solid tumors remains controversial. Thus, we conducted this meta-analysis to summarize the potential value of STMN1 as a biomarker for predicting overall survival in patients with solid tumor. METHODS: We systematically searched eligible studies in PubMed, Web of Science, and EMBASE from the establishment date of these databases to September 2018. Hazard ratio (HR) and its 95% confidence interval (CI) was used to assess the association between STMN1 expression and overall survival. RESULTS: A total of 25 studies with 4625 patients were included in this meta-analysis. Our combined results showed that high STMN1 expression was associated with poor overall survival in solid tumors (HR = 1.85, 95% CI 1.55, 2.21). In general, our subgroup and sensitivity analyses demonstrated that our combined results were stable and reliable. However, from the results of the subgroups we found that high STMN1 expression was not related to overall survival in colorectal cancer and endometrial cancer anymore, suggesting that much caution should be taken to interpret our combined result, and more studies with large sample sizes are required to further explore the prognostic value of STMN1 expression in the specific type of tumors, especially colorectal cancer and endometrial cancer. CONCLUSIONS: STMN1 could serve as a prognostic biomarker and could be developed as a valuable therapeutic target for patients with solid tumors. However, due to the limitations of the present meta-analysis, this conclusion should be taken with caution. Further studies adequately designed are required to confirm our findings.

Expression of CD44v6 in colorectal cancer and its impact on chemosensitivity: Progression in research / 国际外科学杂志

Colorectal cancer is one of the most common malignant tumors,early diagnosis and treatment are the important factors affecting colorectal cancer's prognosis.It has been proved that colorectal cancer's diagnosis combined with biomolecular markers is non-invasive,economical and specific at the same time,biomarkers are valuable in predicting and monitoring the chemoresistance of colorectal cancer.This article mainly reviews the prediction of liver metastasis of colorectal cancer,drug resistance of postoperative chemotherapy in colorectal cancer and the monitoring of drug resistance in the course of chemotherapy by CD44v6.

Changes of Insulin-Like Growth Factor-1 in Serum of Patients with Obstructive Jaundice / 中国普外基础与临床杂志

Objective To study the changes of insulin-like growth factor-1(IGF-1) in serum of patients with obstructive jaundice.Methods The clinical data of 20 patients with obstructive jaundice were collected and the measurement of serum TNF-?,ALT, ALP, endotoxin and IGF-1 were performed. Results The serum IGF-1 in obstructive jaundice was significantly lower than that in gallbladder stone(P